Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study looked at the safety and effectiveness of axicabtagene ciloleucel (AC; Yescarta) in the treatment of unresponsive B-cell lymphoma. Researchers found that AC is a safe and effective treatment for these patients.

Some background

B-cell lymphoma is a cancer of cells in the immune system. It is treated with medication that targets these abnormal cells. This may involve editing T-cells (another type of immune cells) in the laboratory and returning them into the patient to fight cancer. AC is a type of drug which may help to edit these T-cells. It is important to research the safety and effectiveness of this treatment.

Methods & findings

101 patients with larger B-cell lymphomas received AC in this study. Patients were followed for an average time of 27.1 months.

84 (83%) patients responded to the treatment. 59 (58%) patients had no signs of cancer after treatment. Patients continued to respond to treatment for an average of 11.1 months.

108 patients were assessed for safety after treatment. 52 (48%) patients had severe side effects. These included an abnormal response to treatment (11%) and nerve problems (32%).

The bottom line

The study concluded that axicabtagene ciloleucel is safe and effective in the treatment of unresponsive B-cell lymphoma.

The fine print

This study was partially supported by Kite Pharma, the manufacturer of axicabtagene ciloleucel

Published By :

The Lancet. Oncology

Date :

Nov 30, 2018

Original Title :

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

click here to get personalized updates